Novartis Japan’s Oncology Business Chief Demoted Due To SIGN Scandal
This article was originally published in PharmAsia News
Executive Summary
Kazuo Asakawa, Novartis Japan’s oncology head announced he would step down from his position and take a 20% reduction in remuneration until final results of the investigation into the company’s tainted SIGN trials is completed.